First Time Loading...

MacroGenics Inc
NASDAQ:MGNX

Watchlist Manager
MacroGenics Inc Logo
MacroGenics Inc
NASDAQ:MGNX
Watchlist
Price: 16.07 USD -0.19% Market Closed
Updated: Apr 19, 2024

Intrinsic Value

MGNX's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

MacroGenics, Inc. is a clinical-stage biopharmaceutical company, engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of c... [ Read More ]

The intrinsic value of one MGNX stock under the Base Case scenario is 5.48 USD. Compared to the current market price of 16.07 USD, MacroGenics Inc is Overvalued by 66%.

Key Points:
MGNX Intrinsic Value
Base Case
5.48 USD
Overvaluation 66%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
MacroGenics Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling MGNX stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
MacroGenics Inc

Provide an overview of the primary business activities
of MacroGenics Inc.

What unique competitive advantages
does MacroGenics Inc hold over its rivals?

What risks and challenges
does MacroGenics Inc face in the near future?

Has there been any significant insider trading activity
in MacroGenics Inc recently?

Summarize the latest earnings call
of MacroGenics Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for MacroGenics Inc.

Provide P/S
for MacroGenics Inc.

Provide P/E
for MacroGenics Inc.

Provide P/OCF
for MacroGenics Inc.

Provide P/FCFE
for MacroGenics Inc.

Provide P/B
for MacroGenics Inc.

Provide EV/S
for MacroGenics Inc.

Provide EV/GP
for MacroGenics Inc.

Provide EV/EBITDA
for MacroGenics Inc.

Provide EV/EBIT
for MacroGenics Inc.

Provide EV/OCF
for MacroGenics Inc.

Provide EV/FCFF
for MacroGenics Inc.

Provide EV/IC
for MacroGenics Inc.

Show me price targets
for MacroGenics Inc made by professional analysts.

What are the Revenue projections
for MacroGenics Inc?

How accurate were the past Revenue estimates
for MacroGenics Inc?

What are the Net Income projections
for MacroGenics Inc?

How accurate were the past Net Income estimates
for MacroGenics Inc?

What are the EPS projections
for MacroGenics Inc?

How accurate were the past EPS estimates
for MacroGenics Inc?

What are the EBIT projections
for MacroGenics Inc?

How accurate were the past EBIT estimates
for MacroGenics Inc?

Compare the revenue forecasts
for MacroGenics Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of MacroGenics Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of MacroGenics Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of MacroGenics Inc compared to its peers.

Compare the P/E ratios
of MacroGenics Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing MacroGenics Inc with its peers.

Analyze the financial leverage
of MacroGenics Inc compared to its main competitors.

Show all profitability ratios
for MacroGenics Inc.

Provide ROE
for MacroGenics Inc.

Provide ROA
for MacroGenics Inc.

Provide ROIC
for MacroGenics Inc.

Provide ROCE
for MacroGenics Inc.

Provide Gross Margin
for MacroGenics Inc.

Provide Operating Margin
for MacroGenics Inc.

Provide Net Margin
for MacroGenics Inc.

Provide FCF Margin
for MacroGenics Inc.

Show all solvency ratios
for MacroGenics Inc.

Provide D/E Ratio
for MacroGenics Inc.

Provide D/A Ratio
for MacroGenics Inc.

Provide Interest Coverage Ratio
for MacroGenics Inc.

Provide Altman Z-Score Ratio
for MacroGenics Inc.

Provide Quick Ratio
for MacroGenics Inc.

Provide Current Ratio
for MacroGenics Inc.

Provide Cash Ratio
for MacroGenics Inc.

What is the historical Revenue growth
over the last 5 years for MacroGenics Inc?

What is the historical Net Income growth
over the last 5 years for MacroGenics Inc?

What is the current Free Cash Flow
of MacroGenics Inc?

Financials

Balance Sheet Decomposition
MacroGenics Inc

Current Assets 251.3m
Cash & Short-Term Investments 229.8m
Receivables 10.4m
Other Current Assets 11.2m
Non-Current Assets 47.1m
PP&E 45.7m
Other Non-Current Assets 1.4m
Current Liabilities 56.1m
Accounts Payable 6.4m
Accrued Liabilities 28m
Other Current Liabilities 21.7m
Non-Current Liabilities 89.7m
Other Non-Current Liabilities 89.7m
Efficiency

Earnings Waterfall
MacroGenics Inc

Revenue
58.7m USD
Cost of Revenue
-8.2m USD
Gross Profit
50.5m USD
Operating Expenses
-218.8m USD
Operating Income
-168.2m USD
Other Expenses
159.2m USD
Net Income
-9.1m USD

Free Cash Flow Analysis
MacroGenics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

MGNX Profitability Score
Profitability Due Diligence

MacroGenics Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
ROE is Increasing
Positive Revenue Growth Forecast
Negative ROE
20/100
Profitability
Score

MacroGenics Inc's profitability score is 20/100. The higher the profitability score, the more profitable the company is.

MGNX Solvency Score
Solvency Due Diligence

MacroGenics Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Low D/E
Long-Term Solvency
Low Altman Z-Score
56/100
Solvency
Score

MacroGenics Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MGNX Price Targets Summary
MacroGenics Inc

Wall Street analysts forecast MGNX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MGNX is 25.27 USD with a low forecast of 16.16 USD and a high forecast of 31.5 USD.

Lowest
Price Target
16.16 USD
1% Upside
Average
Price Target
25.27 USD
57% Upside
Highest
Price Target
31.5 USD
96% Upside
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

MGNX Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

MGNX Price
MacroGenics Inc

1M 1M
+3%
6M 6M
+251%
1Y 1Y
+135%
3Y 3Y
-50%
5Y 5Y
-1%
10Y 10Y
-16%
Annual Price Range
16.07
52w Low
4.48
52w High
21.47
Price Metrics
Average Annual Return -3.55%
Standard Deviation of Annual Returns 74.79%
Max Drawdown -94%
Shares Statistics
Market Capitalization 997.5m USD
Shares Outstanding 62 432 000
Percentage of Shares Shorted 12.65%

MGNX Return Decomposition
Main factors of price return

What is price return decomposition?

MGNX News

Other Videos

Company Profile

MacroGenics Inc Logo
MacroGenics Inc

Country

United States of America

Industry

Biotechnology

Market Cap

997.5m USD

Dividend Yield

0%

Description

MacroGenics, Inc. is a clinical-stage biopharmaceutical company, engages in discovering and developing antibody-based therapeutics designed to modulate the human immune response for the treatment of cancer. The company is headquartered in Rockville, Maryland and currently employs 427 full-time employees. The company went IPO on 2013-10-10. The company is developing product candidates that target various tumor-associated antigens and immune checkpoint molecules. Its lead pipeline program is MGC018, an antibody-drug conjugate (ADC) that targets B7-H3, a molecule in the B7 family of immune regulator proteins that is expressed by several different tumor types. The company is also developing enoblituzumab, an Fc-optimized monoclonal antibody (mAb) that targets B7-H3 and molecules that target programmed cell death protein 1 (PD-1), a protein that is important in the regulation of the immune system's response to cancer. Its clinical pipeline includes two bispecific DART product candidates that co-engage both PD-1 and lymphocyte-activation gene 3 (LAG-3) (tebotelimab), and PD-1 and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (lorigerlimab). In addition, it is also developing MGD024.

Contact

MARYLAND
Rockville
9704 Medical Center Dr
+13012515172.0
https://www.macrogenics.com/

IPO

2013-10-10

Employees

427

Officers

President, CEO & Director
Dr. Scott Koenig M.D., Ph.D.
Senior VP, CFO & Corporate Secretary
Mr. James Karrels
Chief Operating Officer
Mr. Eric Blasius Risser
Senior Vice President of Technical Operations
Dr. Thomas M. Spitznagel Ph.D.
Senior VP of Research & Chief Scientific Officer
Dr. Ezio Bonvini
Senior VP, General Counsel & Corporate Compliance Officer
Mr. Jeffrey Stuart Peters
Show More
Senior VP of Clinical Development & Chief Medical Officer
Dr. Stephen L. Eck M.D., Ph.D.
VP, Controller & Treasurer
Ms. Lynn Cilinski
Show Less

See Also

Discover More
What is the Intrinsic Value of one MGNX stock?

The intrinsic value of one MGNX stock under the Base Case scenario is 5.48 USD.

Is MGNX stock undervalued or overvalued?

Compared to the current market price of 16.07 USD, MacroGenics Inc is Overvalued by 66%.